



Andrew Badrot
CEO
Centroflora CMS

info@centroflora-cms.com
www.centroflora-cms.com

Luxembourg, July 9, 2014 - Centroflora CMS, a company providing the market with Active Pharmaceutical Ingredients (APIs), acquired assets related to the manufacturing of a group of phytochemical APIs from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies.

Centroflora CMS has also entered a multi-year exclusive agreement with Boehringer Ingelheim in order to supply the market with phytochemical APIs without interruption.

The phytochemical API portfolio acquired from Boehringer Ingelheim includes:

- Atropine
- Atropine Sulfate
- Digoxin
- Digoxin Micron
- Metildigoxin
- Homatropine Methylbromide
- Homatropine Hydrobromide
- Dihydroergotamine Mesylate

In addition, Centroflora CMS will distribute Centroflora's Pilocarpine globally including:

- Pilocarpine Hydrochloride
- Pilocarpine Nitrate

Customers include more than 100 pharmaceutical companies in the United States, Western and Eastern Europe, South America, Asia, Africa and Australia.

Andrew Badrot, Centroflora CMS' CEO stated "We are committed to deliver outstanding service to all constituents in this transaction: our global base of customers on the one hand, and Boehringer Ingelheim on the other. We plan to provide immediately a well-defined roadmap for the continuous supply of the phytochemical APIs to the marketplace."